Paclitaxel/Carboplatin

PreclinicalSmall molecule

Paclitaxel/Carboplatin is one of 80 small molecule programs targeting Endometrial Carcinoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Endometrial CarcinomaActive, not recruiting

Solid TumorRecruiting

Advanced Solid TumorsRecruiting

Endometrial CarcinomaPreclinical

Active, not recruiting

Solid TumorPreclinical

Recruiting

Advanced Solid TumorsPreclinical

Recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

Nubeqa

Bayer

Preclinical

2 2

Fludara

Sanofi

Preclinical

2 3

DATROWAY

Daiichi Sankyo

Preclinical

1 4

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

3 5

Augtyro

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

2 6

Paxil

SSebela Pharmaceuticals Development LLC

Preclinical

1 7

Epivir

GGlaxo Dba Glaxosmithkline

Preclinical

1 8

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 9

Tulmimetostat

Novartis

Preclinical

1 10

Interleukin 2

EEssen Biotech

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Triple-Negative Breast Cancer

NCT04137653

Q4 2029

PreclinicalRecruiting

Solid Tumor

NCT06953323

Clinical

Trials by Indication[1]

Carboplatin2 trials

Paclitaxel/Carboplatin With or Without Cetuximab in CUP

Unknown status·HHeidelberg University·Phase 2·NCT00894569·150 enrolled

CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL

Withdrawn·CCTI BioPharma·Phase 3·NCT00576225

Carcinoma1 trial

Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma

Completed·JJapanese Gynecologic Oncology Group·Phase 3·NCT00226915·637 enrolled

Locally Advanced Head and Neck Cancer1 trial

Trial of Neoadjuvant Therapy With Paclitaxel and Carboplatin in Operable Locally Advanced Head and Neck Cancer Patients

Unknown status·YYonsei University·Phase 2·NCT05294900·79 enrolled

Endometrial Carcinoma1 trial

Combination Chemotherapy of Paclitaxel and Carboplatin With or Without Anthracycline as Aneo Adjuvant Treatment in Advanced Endometrial Carcinoma

Not yet recruiting·SSohag University·N/A·NCT06102252·80 enrolled

Locally Advanced1 trial

Concurrent Endostar, Paclitaxel/Carboplatin and Radiotherapy for Locally Advanced Non-small Cell Lung (RT0902)

Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT01158144·134 enrolled

4 more indications

Triple-Negative Breast Cancer1 trial

Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT

Recruiting·SShengjing Hospital·Phase 3·NCT04137653·1,498 enrolled

Intraperitoneal Chemotherapy1 trial

Uterine Serous Carcinoma and Adjuvant Combined Intraperitoneal Chemotherapy and Radiation

Withdrawn·NNorthwell Health·Phase 1/2·NCT04030000

Non-Small Cell Lung Cancer1 trial

Paclitaxel/Carboplatin (PC) Followed by Gefitinib Versus PC in Advanced Non-small Cell Lung Cancer

Completed·—·Phase 2·NCT01196234·84 enrolled

Solid Tumor1 trial

A Dose-escalation, Dose-expansion and Efficacy Extension Phase I/II Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Preliminary Efficacy of WJB001 Combination Therapy in Patients With Advanced Solid Tumors

Recruiting·WWigen Biomedicine Technology (Shanghai) Co., Ltd.·Preclinical·NCT06953323·86 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Paclitaxel/Carboplatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Paclitaxel/Carboplatin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Paclitaxel/Carboplatin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CTI BioPharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: CCTI BioPharma

Paclitaxel/Carboplatin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2029

Trials by Indication[1]

Carboplatin2 trials

Carcinoma1 trial

Locally Advanced Head and Neck Cancer1 trial

Endometrial Carcinoma1 trial

Locally Advanced1 trial

Triple-Negative Breast Cancer1 trial

Intraperitoneal Chemotherapy1 trial

Non-Small Cell Lung Cancer1 trial

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News